Suppression of HIV p24 antigen and induction of HIV anti-p24 antibody by alpha interferon in patients with chronic hepatitis B.

Abstract

Five HIV p24 antigen (p24Ag)-positive patients received alpha interferon during trials of therapy for hepatitis B. Four of these showed marked falls in p24Ag during treatment. One of the two patients who became p24Ag-negative [corrected] developed anti-p24 antibodies (anti-p24). Five out of nine p24Ag-negative HIV-antibody-positive patients showed a rise in anti-p24 titres during interferon therapy, whereas only two out of six untreated controls showed a similar rise. This study provides evidence that alpha interferon has anti-HIV activity in vivo.

• Authors: M G Brook, D Gor, S M Forster, W Harris, D J Jeffries, H C Thomas
• Journal: AIDS (London, England) (AIDS) Vol. 2 Issue 5 Pg. 391-3 (Oct 1988) ISSN: 0269-9370 [Print] England
• PMID: 3146270 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• HIV Antibodies
• HIV Antigens
• HIV Core Protein p24
• Interferon Type I
• Retroviridae Proteins

Topics

• Adult
• Clinical Trials as Topic
• HIV Antibodies (biosynthesis)
• HIV Antigens (analysis)
• HIV Core Protein p24
• HIV Seropositivity (complications, therapy)
• Hepatitis B (complications, immunology, therapy)
• Humans
• Interferon Type I (therapeutic use)
• Middle Aged
• Random Allocation
• Retroviridae Proteins (immunology)